Literature DB >> 2445076

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids.

S Todo1, A J Demetris, Y Ueda, O Imventarza, K Okuda, A Casavilla, S Cemaj, A Ghalab, V Mazzaferro, B S Rhoe.   

Abstract

The immunosuppressive agent FK permitted increased kidney transplant survival in dogs over a wide dose range, but with weight loss and manifold evidence of toxicity. The best use of FK at low doses was in combination with CyA and Pred.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445076      PMCID: PMC2903874     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  2 in total

1.  Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

Authors:  T Ochiai; K Nakajima; M Nagata; T Suzuki; T Asano; T Uematsu; T Goto; S Hori; T Kenmochi; T Nakagoori
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

2.  IMMUNOSUPPRESSION WITH FR 900506 FOR CANINE KIDNEY AND LIVER TRANSPLANTATION.

Authors:  S Todo; L Makowka; T Starzl
Journal:  Surg Res Commun       Date:  1987-01-01
  2 in total
  26 in total

1.  Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.

Authors:  A C Tsamandas; S M Pham; E C Seaberg; O Pappo; R L Kormos; A Kawai; B P Griffith; A Zeevi; R Duquesnoy; J J Fung; T E Starzl; A J Demetris
Journal:  J Heart Lung Transplant       Date:  1997-07       Impact factor: 10.247

2.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA.

Authors:  A Zeevi; G Eiras; F H Bach; J J Fung; S Todo; T Starzl; R J Duquesnoy
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

4.  Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation.

Authors:  D H Van Thiel; M Iqbal; A Jain; J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

5.  Pathologic observations in human allograft recipients treated with FK 506.

Authors:  A J Demetris; J J Fung; S Todo; B Banner; T Zerbe; G Sysyn; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

6.  The effect of FK 506 on small intestine allotransplantation in the rat.

Authors:  A L Hoffman; L Makowka; X Cai; B Banner; D V Cramer; A Pascualone; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

7.  Species differences in sensitivity of T lymphocytes to immunosuppressive effects of FK 506.

Authors:  G Eiras; O Imventarza; N Murase; Y Ueda; S Todo; T Starzl; R J Duquesnoy; A Zeevi
Journal:  Transplantation       Date:  1990-06       Impact factor: 4.939

8.  Canine total orthotopic small bowel transplantation under FK 506.

Authors:  F Yoshimi; K Nakamura; Y Zhu; M Suzuki; Y Funakoshi; G Carrieri; Y Wu; H Furukawa; A J Demetris; S Todo
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

9.  Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506.

Authors:  A B Jain; R Venkataramanan; J Fung; G Burckart; J Emeigh; W Diven; V Warty; K Abu-Elmagd; S Todo; M Alessiani
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

10.  Enhanced liver regeneration in rats treated with 15-deoxyspergualin alone and in combination with FK 506.

Authors:  M Ohtake; N Okamura; T Sakaguchi; T Aono; S Koyama; K Tsukada; K Yoshida; T Muto
Journal:  Gastroenterol Jpn       Date:  1993-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.